Why do life sciences deals fail? Insights from industry dealmakers

Why do life sciences deals fail? Insights from industry dealmakers

Dealmaking is a key driver of innovation and growth for life sciences companies. Regulation, complexity, scientific discovery and uncertainty are hallmarks of the sector, but can lead to higher-than-average attrition rates for deals.

This report, based on interviews with life sciences dealmaking veterans, looks at key risk factors for buyers and sellers in life sciences deals - and how to avoid them to increase the probability of deal success.

Please complete the form to download the report.

9892 - Final - Report Styling (RGB) front cover reduced.jpg (2480×3508)

Apr 4, 2023 1:51:57 PM
Related Articles
Digital deals in life sciences – what makes them different?

Are you ready for a digital-first future in life sciences? This report explores the challenges and opportunities presented by digital...

Digital deals in life sciences – what makes them different?
by Philip Whitchelo

Are you ready for a digital-first future in life sciences? This report explores the challenges and opportunities presented by digital...

Learn more ->
2025 Annual M&A Success Survey

We are pleased to present the 2025 Annual M&A Success Survey report, published in partnership with Global PMI Partners, E78 Partners and...

2025 Annual M&A Success Survey
by Philip Whitchelo

We are pleased to present the 2025 Annual M&A Success Survey report, published in partnership with Global PMI Partners, E78 Partners and...

Learn more ->
The Future of Industrials: Insights for Investors & M&A Dealmakers

The convergence of technological disruption, environmental, social, and governance (ESG) imperatives, and geopolitical realignment has...

The Future of Industrials: Insights for Investors & M&A Dealmakers
by Philip Whitchelo

The convergence of technological disruption, environmental, social, and governance (ESG) imperatives, and geopolitical realignment has...

Learn more ->